Brensocatib

May 28 2024, Insmed announced positive topline results from landmark ASPEN study of Brensocatib in patients with bronchiectasis.
Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed for the treatment of patients with bronchiectasis, CRSsNP, and other neutrophil-mediated diseases. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Brensocatib is an investigational drug product that has not been approved for any indication in any jurisdiction.